Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

1.

Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.

Ha HT, Griffith KA, Zalupski MM, Schuetze SM, Thomas DG, Lucas DR, Baker LH, Chugh R.

Am J Clin Oncol. 2013 Feb;36(1):77-82. doi: 10.1097/COC.0b013e31823a4970.

PMID:
22237145
[PubMed - indexed for MEDLINE]
2.

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.

Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, Cassier P, Decouvelaere AV, Ranchère D, Kurtz JE, Bergerat JP, Blay JY.

Eur J Cancer. 2012 Nov;48(16):3027-35. doi: 10.1016/j.ejca.2012.05.009. Epub 2012 Jun 7.

PMID:
22682017
[PubMed - indexed for MEDLINE]
3.

High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.

Lee SH, Chang MH, Baek KK, Han B, Lim T, Lee J, Park JO.

Oncology. 2011;80(3-4):257-61. doi: 10.1159/000328795. Epub 2011 Jul 6.

PMID:
21734417
[PubMed - indexed for MEDLINE]
4.

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D'Hondt L, Strauven T, Chaskis C, In't Veld P, Michotte A, De Greve J.

Ann Oncol. 2009 Sep;20(9):1596-603. doi: 10.1093/annonc/mdp032. Epub 2009 Jun 2.

PMID:
19491283
[PubMed - indexed for MEDLINE]
Free Article
5.

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S; Swiss Group for Clinical Cancer Research SAKK.

Clin Cancer Res. 2012 Nov 1;18(21):6049-57. doi: 10.1158/1078-0432.CCR-12-2219. Epub 2012 Sep 12.

PMID:
22977195
[PubMed - indexed for MEDLINE]
Free Article
6.

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.

Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.

Clin Cancer Res. 2008 Dec 1;14(23):7884-95. doi: 10.1158/1078-0432.CCR-07-5165.

PMID:
19047118
[PubMed - indexed for MEDLINE]
Free Article
7.

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW.

Invest New Drugs. 2012 Aug;30(4):1607-13. doi: 10.1007/s10637-011-9703-8. Epub 2011 Jun 25.

PMID:
21706149
[PubMed - indexed for MEDLINE]
8.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group.

Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16.

PMID:
22595799
[PubMed - indexed for MEDLINE]
9.

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.

Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ.

Eur J Cancer. 2010 Jul;46(10):1829-34. doi: 10.1016/j.ejca.2010.03.017. Epub 2010 Apr 24.

PMID:
20418097
[PubMed - indexed for MEDLINE]
10.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
[PubMed - indexed for MEDLINE]
11.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD.

J Clin Oncol. 2012 Jan 1;30(1):78-84. doi: 10.1200/JCO.2011.35.6329. Epub 2011 Nov 7.

PMID:
22067397
[PubMed - indexed for MEDLINE]
Free Article
12.

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV.

J Thorac Oncol. 2010 Nov;5(11):1855-8. doi: 10.1097/JTO.0b013e3181f0bee0.

PMID:
20975380
[PubMed - indexed for MEDLINE]
13.

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP.

Cancer. 2007 Aug 1;110(3):581-9.

PMID:
17583545
[PubMed - indexed for MEDLINE]
Free Article
14.

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.

Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21.

PMID:
20413299
[PubMed - indexed for MEDLINE]
15.

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.

Kim SY, Shim EK, Yeo HY, Baek JY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, Jung KH, Chang HJ.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):201-7. doi: 10.1016/j.ijrobp.2012.03.048. Epub 2012 Jun 5.

PMID:
22672749
[PubMed - indexed for MEDLINE]
16.

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG.

Lancet Oncol. 2013 Apr;14(4):371-82. doi: 10.1016/S1470-2045(13)70049-4. Epub 2013 Mar 8.

PMID:
23477833
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis.

Reichardt P, Pink D, Tilgner J, Kretzschmar A, Thuss-Patience PC, Dörken B.

Onkologie. 2002 Dec;25(6):541-6.

PMID:
12566899
[PubMed - indexed for MEDLINE]
18.

High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.

Yalcin B, Pamir A, Buyukcelik A, Utkan G, Akbulut H, Demirkazik A, Icli F.

Exp Oncol. 2004 Dec;26(4):320-5.

PMID:
15627067
[PubMed - indexed for MEDLINE]
19.

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.

Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B.

Int J Oncol. 2012 Sep;41(3):1029-35. doi: 10.3892/ijo.2012.1539. Epub 2012 Jun 29.

PMID:
22752145
[PubMed - indexed for MEDLINE]
20.

Phase II study on lapatinib in advanced EGFR-positive chordoma.

Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, Gronchi A, Pilotti S, Casali PG.

Ann Oncol. 2013 Jul;24(7):1931-6. doi: 10.1093/annonc/mdt117. Epub 2013 Apr 4.

PMID:
23559153
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk